|Dr. Harlan W. Waksal||Pres, CEO & Director||1.08M||N/A||1953|
|Mr. Steven Meehan||Exec. VP & CFO||37.5k||N/A||1965|
|Mr. Kyle Carver||Controller & Principal Accounting Officer||N/A||N/A||N/A|
|Mr. Gregory S. Moss||EVP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer||N/A||N/A||1984|
|Dr. John L. Ryan||Chief Medical Officer & Exec. VP||N/A||N/A||1943|
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.
Kadmon Holdings, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 4; Compensation: 9.